ClinicalTrials.gov record
Active, not recruiting Phase 1Phase 2 Interventional

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

ClinicalTrials.gov ID: NCT05682443

Public ClinicalTrials.gov record NCT05682443. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 12:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized Study of ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Progressed on Androgen Receptor (AR) Pathway Inhibition

Study identification

NCT ID
NCT05682443
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
OncoC4, Inc.
Industry
Enrollment
148 participants

Conditions and interventions

Interventions

  • ONC-392 high Drug
  • ONC-392 low Drug
  • lutetium Lu 177 vipivotide tetraxetan Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 10, 2023
Primary completion
Jun 29, 2026
Completion
Jun 29, 2027
Last update posted
Apr 28, 2026

2023 – 2027

United States locations

U.S. sites
23
U.S. states
17
U.S. cities
22
Facility City State ZIP Site status
UC Davis Comprehensive Cancer Center Sacramento California 95817
Rocky Mountain Cancer Centers USOR Aurora Colorado 80012
Moffitt Cancer Cancer Tampa Florida 33612
Emory University Winship Cancer Institute Atlanta Georgia 30322
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland 21202
Chesapeake Urology Research Associates Towson Maryland 21204
Lahey Hospital & Medical Center Burlington Massachusetts 01805
University of Mississippi Medical Center Jackson Mississippi 39216
XCancer/GU Research Network Omaha Nebraska 68130
Rutgers Cancer Institute New Brunswick New Jersey 08901
New Mexico Oncology Hematology Consultants Albuquerque New Mexico 87109
Roswell Park Comprehensive Cancer Center Buffalo New York 14203
NYU Langone Health, Laura & Isaac Perlmutter Cancer Center New York New York 10016
Columbia University Irving Cancer Center New York New York 10032
UNC North Carolina Comprehensive Cancer Care Center Chapel Hill North Carolina 27514
Duke Cancer Center Durham North Carolina 27710
The Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
OHSU Knight Cancer Institute Portland Oregon 97210
UT Southwestern Medical Center Dallas Texas 75390
Virginia Cancer Specialists USOR Fairfax Virginia 22031
Virginia Oncology Associates USOR Norfolk Virginia 23502
Oncology and Hematology Associates Of Southwest Virginia USOR Norton Virginia 24273
UW Carbone Cancer Center Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05682443, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 28, 2026 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05682443 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →